Add to ORKGIn this communication, we will report the development of a capillary electrophoresis approach for the screening of fragments towards thrombin and FXIIa. We performed direct and competitive ACE-binding assays for the screening of molecules at physiological pH.Development of new compounds targeting coagulation factor XIIa using innovative microfluidic assays in the context of fragment-based drug discover
Over the last decade, the coagulation factor XIIa (FXIIa) has seen renewed interest as a therapeutic...
With the emergence of novel pharmaceutical targets, there is an imperative need for fast, reliable a...
Methods for identifying chemical inhibitors of protein–protein interactions (PPIs) are often prone t...
In this communication, we will report the development of a capillary electrophoresis approach for th...
peer reviewedTackling thrombotic disorders without affecting the hemostatic capacity remains a chall...
Coagulation factor XIIa (FXIIa) is a S1A serine protease implicated in several physiological pathway...
The discovery of lead compounds that can modulate the activity of a biological target is essential t...
The discovery of lead compounds that can modulate the activity of a biological target is essential t...
Coagulation factor XIIa (FXIIa) emerges as a promising target for thromboses induced by blood-contac...
peer reviewedIn this study, a partial-filling affinity capillary electrophoresis (pf-ACE) method was...
peer reviewedFragment-based lead discovery is a usual strategy in drug discovery to identify innovat...
peer reviewedIntroduction Fragment-based drug discovery is a usual approach to identify innovative ...
peer reviewedWith the emergence of more challenging targets, a relatively new approach, fragment-bas...
peer reviewedFragment-based drug discovery is a usual approach to identify innovative lead compounds...
Development of new compounds targeting coagulation factor XIIa using innovative microfluidic assays ...
Over the last decade, the coagulation factor XIIa (FXIIa) has seen renewed interest as a therapeutic...
With the emergence of novel pharmaceutical targets, there is an imperative need for fast, reliable a...
Methods for identifying chemical inhibitors of protein–protein interactions (PPIs) are often prone t...
In this communication, we will report the development of a capillary electrophoresis approach for th...
peer reviewedTackling thrombotic disorders without affecting the hemostatic capacity remains a chall...
Coagulation factor XIIa (FXIIa) is a S1A serine protease implicated in several physiological pathway...
The discovery of lead compounds that can modulate the activity of a biological target is essential t...
The discovery of lead compounds that can modulate the activity of a biological target is essential t...
Coagulation factor XIIa (FXIIa) emerges as a promising target for thromboses induced by blood-contac...
peer reviewedIn this study, a partial-filling affinity capillary electrophoresis (pf-ACE) method was...
peer reviewedFragment-based lead discovery is a usual strategy in drug discovery to identify innovat...
peer reviewedIntroduction Fragment-based drug discovery is a usual approach to identify innovative ...
peer reviewedWith the emergence of more challenging targets, a relatively new approach, fragment-bas...
peer reviewedFragment-based drug discovery is a usual approach to identify innovative lead compounds...
Development of new compounds targeting coagulation factor XIIa using innovative microfluidic assays ...
Over the last decade, the coagulation factor XIIa (FXIIa) has seen renewed interest as a therapeutic...
With the emergence of novel pharmaceutical targets, there is an imperative need for fast, reliable a...
Methods for identifying chemical inhibitors of protein–protein interactions (PPIs) are often prone t...